{"id":47483,"date":"2026-07-22T10:31:14","date_gmt":"2026-07-22T13:31:14","guid":{"rendered":"https:\/\/www.grupomedcof.com.br\/blog\/?p=47483"},"modified":"2026-07-22T10:31:15","modified_gmt":"2026-07-22T13:31:15","slug":"anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia","status":"publish","type":"post","link":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/","title":{"rendered":"Anvisa aprova novas indica\u00e7\u00f5es terap\u00eauticas para c\u00e2ncer renal e hemofilia"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410-1024x576.jpg\" alt=\"\" class=\"wp-image-47484\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410-1024x576.jpg 1024w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410-300x169.jpg 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410-768x432.jpg 768w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410-1536x864.jpg 1536w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410-747x420.jpg 747w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410-150x84.jpg 150w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410-696x392.jpg 696w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410-1068x601.jpg 1068w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410.jpg 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">A <strong>Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) <\/strong>aprovou novas indica\u00e7\u00f5es terap\u00eauticas para dois medicamentos j\u00e1 registrados no pa\u00eds, ampliando as op\u00e7\u00f5es de tratamento para pacientes com <strong>c\u00e2ncer renal<\/strong> e <strong>hemofilia A<\/strong>. A decis\u00e3o representa um avan\u00e7o regulat\u00f3rio importante, pois permite que terapias j\u00e1 dispon\u00edveis possam ser utilizadas em novos cen\u00e1rios cl\u00ednicos, com base em evid\u00eancias de efic\u00e1cia e seguran\u00e7a.<\/p>\n\n\n\n<h2 id=\"h-o-que-mudou-nas-aprovacoes-da-anvisa\" class=\"wp-block-heading\"><strong>O que mudou nas aprova\u00e7\u00f5es da Anvisa?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Diferentemente do registro de um novo medicamento, a aprova\u00e7\u00e3o de uma <strong>nova indica\u00e7\u00e3o terap\u00eautica<\/strong> permite que um f\u00e1rmaco j\u00e1 comercializado seja utilizado para uma condi\u00e7\u00e3o cl\u00ednica adicional ou em uma nova linha de tratamento.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nesse processo, a Anvisa avalia estudos cl\u00ednicos que demonstrem benef\u00edcios relevantes para a nova popula\u00e7\u00e3o de pacientes, mantendo crit\u00e9rios rigorosos relacionados \u00e0 qualidade, efic\u00e1cia e seguran\u00e7a.<\/p>\n\n\n\n<h2 id=\"h-nova-indicacao-para-cancer-renal-amplia-opcoes-de-tratamento\" class=\"wp-block-heading\"><strong>Nova indica\u00e7\u00e3o para c\u00e2ncer renal amplia op\u00e7\u00f5es de tratamento<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Uma das aprova\u00e7\u00f5es contempla pacientes com <strong>carcinoma de c\u00e9lulas renais (CCR)<\/strong>, o tipo mais comum de c\u00e2ncer de rim em adultos, respons\u00e1vel por cerca de 90% dos casos da doen\u00e7a.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O<strong> tratamento do <a href=\"https:\/\/www.grupomedcof.com.br\/blog\/vacina-contra-cancer-renal-tem-resultados-esperancosos\/\" target=\"_blank\" rel=\"noreferrer noopener\">c\u00e2ncer renal<\/a><\/strong> evoluiu significativamente na \u00faltima d\u00e9cada, especialmente com a incorpora\u00e7\u00e3o de terapias-alvo e imunoterapias. A amplia\u00e7\u00e3o das indica\u00e7\u00f5es aprovada pela Anvisa acompanha esse movimento, permitindo que um medicamento j\u00e1 registrado possa ser utilizado em uma nova estrat\u00e9gia terap\u00eautica baseada em evid\u00eancias cl\u00ednicas recentes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Na pr\u00e1tica, isso significa que m\u00e9dicos passam a contar com uma alternativa adicional para definir o tratamento mais adequado conforme fatores como:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Estadiamento da doen\u00e7a;<\/li>\n\n\n\n<li>Perfil cl\u00ednico do paciente;<\/li>\n\n\n\n<li>Tratamentos previamente realizados;<\/li>\n\n\n\n<li>Avalia\u00e7\u00e3o de risco e progn\u00f3stico.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Embora a decis\u00e3o regulat\u00f3ria n\u00e3o altere, por si s\u00f3, protocolos do Sistema \u00danico de Sa\u00fade (SUS) ou da sa\u00fade suplementar, ela amplia o arsenal terap\u00eautico dispon\u00edvel no pa\u00eds.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.grupomedcof.com.br\/cofletters\/?clientId=&amp;utm_campaign=newsletter&amp;utm_medium=banner&amp;utm_source=blog&amp;utm_content=inscricao#https:\/\/www.grupomedcof.com.br\/blog\/\" target=\"_blank\" rel=\" noreferrer noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"320\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-1024x320.png\" alt=\"banner\" class=\"wp-image-39227\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-1024x320.png 1024w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-300x94.png 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-768x240.png 768w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-150x47.png 150w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-696x218.png 696w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-1068x334.png 1068w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1.png 1343w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 id=\"h-hemofilia-a-passa-a-contar-com-nova-possibilidade-terapeutica\" class=\"wp-block-heading\"><strong>Hemofilia A passa a contar com nova possibilidade terap\u00eautica<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A segunda aprova\u00e7\u00e3o envolve pacientes com <strong><a href=\"https:\/\/www.grupomedcof.com.br\/blog\/novo-medicamento-tratamento-hemofilia\/\" target=\"_blank\" rel=\"noreferrer noopener\">hemofilia A<\/a><\/strong>, doen\u00e7a heredit\u00e1ria causada pela defici\u00eancia do fator VIII da coagula\u00e7\u00e3o, caracterizada por epis\u00f3dios hemorr\u00e1gicos espont\u00e2neos ou desencadeados por traumas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Com a nova indica\u00e7\u00e3o aprovada pela Anvisa, um medicamento biol\u00f3gico j\u00e1 registrado poder\u00e1 ser utilizado em uma popula\u00e7\u00e3o ampliada de pacientes, oferecendo mais uma alternativa para preven\u00e7\u00e3o de sangramentos e manejo da doen\u00e7a.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nos \u00faltimos anos, o tratamento da hemofilia passou por mudan\u00e7as importantes com o desenvolvimento de terapias de a\u00e7\u00e3o prolongada e medicamentos que reduzem a frequ\u00eancia de infus\u00f5es intravenosas, melhorando a ades\u00e3o ao tratamento e a qualidade de vida dos pacientes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A amplia\u00e7\u00e3o da indica\u00e7\u00e3o refor\u00e7a essa tend\u00eancia de personaliza\u00e7\u00e3o terap\u00eautica, permitindo maior flexibilidade na escolha do esquema de tratamento conforme as caracter\u00edsticas cl\u00ednicas individuais.<\/p>\n\n\n\n<h2 id=\"h-qual-a-importancia-das-novas-indicacoes-terapeuticas\" class=\"wp-block-heading\"><strong>Qual a import\u00e2ncia das novas indica\u00e7\u00f5es terap\u00eauticas?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A aprova\u00e7\u00e3o de novas indica\u00e7\u00f5es possui impacto que vai al\u00e9m da disponibilidade de medicamentos.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Do ponto de vista regulat\u00f3rio e assistencial, essas decis\u00f5es:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ampliam as op\u00e7\u00f5es de tratamento para m\u00e9dicos e pacientes;<\/li>\n\n\n\n<li>Incorporam evid\u00eancias cient\u00edficas mais recentes \u00e0 pr\u00e1tica cl\u00ednica;<\/li>\n\n\n\n<li>Favorecem abordagens terap\u00eauticas mais individualizadas;<\/li>\n\n\n\n<li>Estimulam a atualiza\u00e7\u00e3o de protocolos cl\u00ednicos e diretrizes ao longo do tempo.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-o-que-acontece-apos-a-aprovacao-da-anvisa\" class=\"wp-block-heading\"><strong>O que acontece ap\u00f3s a aprova\u00e7\u00e3o da Anvisa?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A autoriza\u00e7\u00e3o da Anvisa permite que o fabricante comercialize o medicamento com a nova indica\u00e7\u00e3o em bula. Entretanto, sua utiliza\u00e7\u00e3o em larga escala depende de outras etapas, como:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Atualiza\u00e7\u00e3o das bulas e materiais t\u00e9cnicos;<\/li>\n\n\n\n<li>Incorpora\u00e7\u00e3o em protocolos institucionais;<\/li>\n\n\n\n<li>Avalia\u00e7\u00e3o pela Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS (Conitec), quando houver interesse de disponibiliza\u00e7\u00e3o na rede p\u00fablica;<\/li>\n\n\n\n<li>Defini\u00e7\u00e3o de cobertura pelos sistemas de sa\u00fade, quando aplic\u00e1vel.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Assim, a aprova\u00e7\u00e3o regulat\u00f3ria representa um passo importante, mas n\u00e3o significa necessariamente incorpora\u00e7\u00e3o imediata ao SUS.<\/p>\n\n\n\n<h2 id=\"h-quer-acompanhar-as-principais-atualizacoes-da-medicina-e-da-residencia-medica\" class=\"wp-block-heading\"><strong>Quer acompanhar as principais atualiza\u00e7\u00f5es da medicina e da resid\u00eancia m\u00e9dica?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"h-\">No Blog da MedCof, voc\u00ea encontra <strong>not\u00edcias sobre decis\u00f5es da Anvisa, novidades terap\u00eauticas, mudan\u00e7as em protocolos cl\u00ednicos<\/strong> e conte\u00fados voltados para quem deseja manter a <strong>pr\u00e1tica m\u00e9dica <\/strong>sempre atualizada e baseada nas melhores evid\u00eancias.<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<div class=\"youtube-embed\" data-video_id=\"TthZQXr9JGU\"><iframe loading=\"lazy\" title=\"Como \u00e9 a Resid\u00eancia de CL\u00cdNICA M\u00c9DICA em SP? (Einstein, HC-FMUSP) | SingularCast\" width=\"696\" height=\"392\" src=\"https:\/\/www.youtube.com\/embed\/TthZQXr9JGU?feature=oembed&#038;enablejsapi=1\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/div>\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>A Anvisa aprovou novas indica\u00e7\u00f5es terap\u00eauticas para medicamentos usados no tratamento do c\u00e2ncer renal e da hemofilia A. Entenda o que muda na pr\u00e1tica cl\u00ednica.<\/p>\n","protected":false},"author":20,"featured_media":47484,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[240],"tags":[1685,2626,2285,805],"ppma_author":[3616],"class_list":["post-47483","post","type-post","status-publish","format-standard","has-post-thumbnail","category-noticias","tag-anvisa","tag-cancer-renal","tag-hemofilia","tag-sus"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.1 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Anvisa aprova novas indica\u00e7\u00f5es para c\u00e2ncer renal e hemofilia; veja o que muda<\/title>\n<meta name=\"description\" content=\"A Anvisa aprovou novas indica\u00e7\u00f5es terap\u00eauticas para medicamentos usados no tratamento do c\u00e2ncer renal e da hemofilia A. Entenda o que muda na pr\u00e1tica cl\u00ednica.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anvisa aprova novas indica\u00e7\u00f5es terap\u00eauticas para c\u00e2ncer renal e hemofilia\" \/>\n<meta property=\"og:description\" content=\"A Anvisa aprovou novas indica\u00e7\u00f5es terap\u00eauticas para medicamentos usados no tratamento do c\u00e2ncer renal e da hemofilia A. Entenda o que muda na pr\u00e1tica cl\u00ednica.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog de Medcof: conte\u00fados, editais, revalida e mais!\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/MedCofQbank\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-22T13:31:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-22T13:31:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Leila Menzel\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Leila Menzel\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\\\/\"},\"author\":{\"name\":\"Leila Menzel\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#\\\/schema\\\/person\\\/6c9d76c2d1abb71d1cbff62ad7c6f83e\"},\"headline\":\"Anvisa aprova novas indica\u00e7\u00f5es terap\u00eauticas para c\u00e2ncer renal e hemofilia\",\"datePublished\":\"2026-07-22T13:31:14+00:00\",\"dateModified\":\"2026-07-22T13:31:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\\\/\"},\"wordCount\":764,\"publisher\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Blog-MedCof-2026-07-22T102800.410.jpg\",\"keywords\":[\"Anvisa\",\"C\u00e2ncer renal\",\"Hemofilia\",\"SUS\"],\"articleSection\":[\"Not\u00edcias\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\\\/\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\\\/\",\"name\":\"Anvisa aprova novas indica\u00e7\u00f5es para c\u00e2ncer renal e hemofilia; veja o que muda\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Blog-MedCof-2026-07-22T102800.410.jpg\",\"datePublished\":\"2026-07-22T13:31:14+00:00\",\"dateModified\":\"2026-07-22T13:31:15+00:00\",\"description\":\"A Anvisa aprovou novas indica\u00e7\u00f5es terap\u00eauticas para medicamentos usados no tratamento do c\u00e2ncer renal e da hemofilia A. Entenda o que muda na pr\u00e1tica cl\u00ednica.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Blog-MedCof-2026-07-22T102800.410.jpg\",\"contentUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Blog-MedCof-2026-07-22T102800.410.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anvisa aprova novas indica\u00e7\u00f5es terap\u00eauticas para c\u00e2ncer renal e hemofilia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/\",\"name\":\"Blog de Medcof: conte\u00fados, editais, revalida e mais!\",\"description\":\"Acesso o blog de MedCof! Seu portal de conte\u00fados sobre resid\u00eancia m\u00e9dica, an\u00e1lise e editais e muito mais. Clique e confira!\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#organization\"},\"alternateName\":\"Blog de Medcof: conte\u00fados, editais, revalida e mais!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#organization\",\"name\":\"Grupo MedCof\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/logo-medcof.png\",\"contentUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/logo-medcof.png\",\"width\":768,\"height\":269,\"caption\":\"Grupo MedCof\"},\"image\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/MedCofQbank\\\/\",\"https:\\\/\\\/www.instagram.com\\\/grupomedcof\\\/\",\"https:\\\/\\\/br.linkedin.com\\\/company\\\/medcof\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCdHMuOHKICxcHwecxN8P-AA\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#\\\/schema\\\/person\\\/6c9d76c2d1abb71d1cbff62ad7c6f83e\",\"name\":\"Leila Menzel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/cropped-eu-96x96.jpeg19a74936d997c0a8b3031618467fa1d0\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/cropped-eu-96x96.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/cropped-eu-96x96.jpeg\",\"caption\":\"Leila Menzel\"},\"description\":\"Estudante do 7\u00b0 semestre de jornalismo. Atuo na cobertura de not\u00edcias e atualiza\u00e7\u00f5es sobre sa\u00fade, com foco em resid\u00eancia m\u00e9dica.\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/author\\\/leila-menzel\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Anvisa aprova novas indica\u00e7\u00f5es para c\u00e2ncer renal e hemofilia; veja o que muda","description":"A Anvisa aprovou novas indica\u00e7\u00f5es terap\u00eauticas para medicamentos usados no tratamento do c\u00e2ncer renal e da hemofilia A. Entenda o que muda na pr\u00e1tica cl\u00ednica.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/","og_locale":"pt_BR","og_type":"article","og_title":"Anvisa aprova novas indica\u00e7\u00f5es terap\u00eauticas para c\u00e2ncer renal e hemofilia","og_description":"A Anvisa aprovou novas indica\u00e7\u00f5es terap\u00eauticas para medicamentos usados no tratamento do c\u00e2ncer renal e da hemofilia A. Entenda o que muda na pr\u00e1tica cl\u00ednica.","og_url":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/","og_site_name":"Blog de Medcof: conte\u00fados, editais, revalida e mais!","article_publisher":"https:\/\/www.facebook.com\/MedCofQbank\/","article_published_time":"2026-07-22T13:31:14+00:00","article_modified_time":"2026-07-22T13:31:15+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410.jpg","type":"image\/jpeg"}],"author":"Leila Menzel","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Leila Menzel","Est. tempo de leitura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/#article","isPartOf":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/"},"author":{"name":"Leila Menzel","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#\/schema\/person\/6c9d76c2d1abb71d1cbff62ad7c6f83e"},"headline":"Anvisa aprova novas indica\u00e7\u00f5es terap\u00eauticas para c\u00e2ncer renal e hemofilia","datePublished":"2026-07-22T13:31:14+00:00","dateModified":"2026-07-22T13:31:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/"},"wordCount":764,"publisher":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/#organization"},"image":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410.jpg","keywords":["Anvisa","C\u00e2ncer renal","Hemofilia","SUS"],"articleSection":["Not\u00edcias"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/","url":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/","name":"Anvisa aprova novas indica\u00e7\u00f5es para c\u00e2ncer renal e hemofilia; veja o que muda","isPartOf":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/#primaryimage"},"image":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410.jpg","datePublished":"2026-07-22T13:31:14+00:00","dateModified":"2026-07-22T13:31:15+00:00","description":"A Anvisa aprovou novas indica\u00e7\u00f5es terap\u00eauticas para medicamentos usados no tratamento do c\u00e2ncer renal e da hemofilia A. Entenda o que muda na pr\u00e1tica cl\u00ednica.","breadcrumb":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/#primaryimage","url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410.jpg","contentUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/07\/Blog-MedCof-2026-07-22T102800.410.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-novas-indicacoes-terapeuticas-para-cancer-renal-e-hemofilia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/www.grupomedcof.com.br\/blog\/"},{"@type":"ListItem","position":2,"name":"Anvisa aprova novas indica\u00e7\u00f5es terap\u00eauticas para c\u00e2ncer renal e hemofilia"}]},{"@type":"WebSite","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#website","url":"https:\/\/www.grupomedcof.com.br\/blog\/","name":"Blog de Medcof: conte\u00fados, editais, revalida e mais!","description":"Acesso o blog de MedCof! Seu portal de conte\u00fados sobre resid\u00eancia m\u00e9dica, an\u00e1lise e editais e muito mais. Clique e confira!","publisher":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/#organization"},"alternateName":"Blog de Medcof: conte\u00fados, editais, revalida e mais!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.grupomedcof.com.br\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#organization","name":"Grupo MedCof","url":"https:\/\/www.grupomedcof.com.br\/blog\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2022\/01\/logo-medcof.png","contentUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2022\/01\/logo-medcof.png","width":768,"height":269,"caption":"Grupo MedCof"},"image":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/MedCofQbank\/","https:\/\/www.instagram.com\/grupomedcof\/","https:\/\/br.linkedin.com\/company\/medcof","https:\/\/www.youtube.com\/channel\/UCdHMuOHKICxcHwecxN8P-AA"]},{"@type":"Person","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#\/schema\/person\/6c9d76c2d1abb71d1cbff62ad7c6f83e","name":"Leila Menzel","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/09\/cropped-eu-96x96.jpeg19a74936d997c0a8b3031618467fa1d0","url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/09\/cropped-eu-96x96.jpeg","contentUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/09\/cropped-eu-96x96.jpeg","caption":"Leila Menzel"},"description":"Estudante do 7\u00b0 semestre de jornalismo. Atuo na cobertura de not\u00edcias e atualiza\u00e7\u00f5es sobre sa\u00fade, com foco em resid\u00eancia m\u00e9dica.","url":"https:\/\/www.grupomedcof.com.br\/blog\/author\/leila-menzel\/"}]}},"authors":[{"term_id":3616,"user_id":20,"is_guest":0,"slug":"leila-menzel","display_name":"Leila Menzel","avatar_url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/09\/cropped-eu-96x96.jpeg","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/posts\/47483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/comments?post=47483"}],"version-history":[{"count":1,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/posts\/47483\/revisions"}],"predecessor-version":[{"id":47485,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/posts\/47483\/revisions\/47485"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/media\/47484"}],"wp:attachment":[{"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/media?parent=47483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/categories?post=47483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/tags?post=47483"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/ppma_author?post=47483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}